This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 14:37, 17 August 2011 (CAS#, etc.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:37, 17 August 2011 by Edgar181 (talk | contribs) (CAS#, etc.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
 | |
| Clinical data | |
|---|---|
| Other names | Glycerol trioctanoate; Tricaprylin |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.007.898  |
| Chemical and physical data | |
| Formula | C27H50O6 |
| Molar mass | 470.68 g · mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Caprylidene (trade name Axona) is a medical food that was approved in March 2009 by the U.S. Food and Drug Administration for the "clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease". Glucose metabolism by the brain is impaired in Alzheimer's disease, and it is proposed that ketone bodies may provide an alternative energy source. Caprylidene is a powdered form of caprylic triglyceride, a medium chain triglyceride (MCT) in which three molecules of caprylic acid are esterified with glycerol.
See also
References
- FDA-Approved Drugs 2009: Axona (caprylidene) CenterWatch. Cited 30 November 2009.
- Axona Drugs.com. Cited 30 November 2009.
Further reading
- Accera. (February 2011). Axona Description (Prescribing Information). Retrieved April 26, 2011 from www.about-axona.com.
- Henderson ST. (July 2008). Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 5 (3): 470-480. PMID 18625458.
External links
This article is a stub. You can help Misplaced Pages by expanding it. |